Bluebird to seek approvals for three treatments by end of 2019
(Reuters) - U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, Chief Executive Nick Leschly announced on Tuesday.
from Reuters: Health News http://reut.rs/2CJ013w
http://bit.ly/2zwRqiM